at the end of that story:
------
"If Mesoblast could capture 5 per cent market share for its leading six indications, it would translate into annual revenues of about $4.5bn, placing it in the same vicinity as CSL," Macquarie Equities said last week
------
We will be bigger than CSL one day IMO - perhaps even much bigger! Many more than 6 applications, and potentially much more than 5% market share.
another article in the australian, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |